NR3C1 and type 2 diabetes mellitus: For the evaluation of GC-sensitivity in PBMCs of T2D patients, Panagiotou et al. assessed the expression levels of the GR-transactivated genes GILZ and FKBP5, in basal condition and after Dex treatment.